nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-220-12-130-139nogr-2660Research ArticleОБЗОРREVIEWРоль повышенной проницаемости кишечника в развитии и прогрессировании заболеваний печениRole of increased intestinal permeability in the development and progression of liver diseaseshttps://orcid.org/0000-0001-7367-9219МехтиевС. Н.MekhtiyevS. N.sabirm@mail.ruhttps://orcid.org/0000-0002-0842-855XМехтиеваО. А.MekhtiyevaO. A.noemail@neicon.ruhttps://orcid.org/0000-0001-7379-6896БеркоО. М.BerkoO. M.noemail@neicon.ruhttps://orcid.org/0000-0002-3898-2017КолодкинА. М.KolodkinA. M.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Первый Санкт-Петербургский государственный медицинский университет имени академика И. П. Павлова» Министерства здравоохранения Российской Федерации; Гастроэнтерологический центр «Эксперт»РоссияAcademician I. P. Pavlov First St. Petersburg State Medical University; Gastroenterological Center “Expert”Russian FederationФедеральное государственное бюджетное учреждение «Северо-Западный окружной научно-клинический центр имени Л. Г. Соколова Федерального медико-биологического агентства России»РоссияNorth-Western Regional Scientific and Clinical Center named after L. G. Sokolov of the Federal Medical Biological AgencyRussian FederationНаучное общество «Микробиота»РоссияScientific Society “Microbiota”Russian Federation202318122023012130139Copyright © Мехтиев С.Н., Мехтиева О.А., Берко О.М., Колодкин А.М., 20232023Мехтиев С.Н., Мехтиева О.А., Берко О.М., Колодкин А.М.Mekhtiyev S.N., Mekhtiyeva O.A., Berko O.M., Kolodkin A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2660

Феномен «дырявого кишечника» или повышенной проницаемости кишечника (ППК) активно изучается на протяжении последних двух десятилетий. Доказана его роль в развитии синдрома раздраженной кишки и ряда других патологий кишечника. В то же время накапливается все больше сведений о влиянии ППК на возникновение и прогрессирование заболеваний печени. В данной статье представлен литературный обзор последних материалов о взаимосвязи кишечника и печени через феномен ППК и новые потенциальные точки для терапевтического воздействия.

The phenomenon of “leaky gut” or increased intestinal permeability has been actively studied over the past two decades. Its role has been proven in the development of irritable bowel syndrome and a number of other intestinal pathologies. At the same time, more and more information is accumulating on the effect of “leaky gut” on the occurrence and progression of liver diseases. This article presents a literature review of recent materials on the relationship between the intestine and the liver through the phenomenon of “leaky gut” and new potential points for therapeutic intervention.

кишечный барьерповышенная проницаемость кишечникамикробиотахронические заболевания печенипребиотикиметабиотикиintestinal barrierleaky gutmicrobiotachronic liver diseasesprebioticsmetabioticsReferencesPortincasa P, Bonfrate L, Khalil M, Angelis M, Calabrese FM, D’Amato M, Wang DQ, Di Ciaula A.Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines. 2021 Dec 31;10(1):83. doi: 10.3390/biomedicines10010083.Portincasa P, Bonfrate L, Khalil M, Angelis M, Calabrese FM, D’Amato M, Wang DQ, Di Ciaula A.Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines. 2021 Dec 31;10(1):83. doi: 10.3390/biomedicines10010083.Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, Satokari R. The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation. Nutrients. 2018 Jul 29;10(8):988. doi: 10.3390/nu10080988.Hiippala K, Jouhten H, Ronkainen A, Hartikainen A, Kainulainen V, Jalanka J, Satokari R. The Potential of Gut Commensals in Reinforcing Intestinal Barrier Function and Alleviating Inflammation. Nutrients. 2018 Jul 29;10(8):988. doi: 10.3390/nu10080988.Bauer M.A., Kainz K., Carmona-Gutierrez D., Madeo F. Microbial wars: Competition in ecological niches and within the microbiome. Microb Cell. 2018 May 7;5(5):215-219. doi: 10.15698/mic2018.05.628.Bauer M.A., Kainz K., Carmona-Gutierrez D., Madeo F. Microbial wars: Competition in ecological niches and within the microbiome. Microb Cell. 2018 May 7;5(5):215-219. doi: 10.15698/mic2018.05.628.Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. Tissue Barriers. 2015 Apr 3;3(1-2): e982426. doi: 10.4161/21688370.2014.982426.Cornick S, Tawiah A, Chadee K. Roles and regulation of the mucus barrier in the gut. Tissue Barriers. 2015 Apr 3;3(1-2): e982426. doi: 10.4161/21688370.2014.982426.Macpherson A.J., Geuking M. B., McCoy K. D. Homeland security: IgA immunity at the frontiers of the body. Trends Immunol. 2012 Apr;33(4):160-7. doi: 10.1016/j.it.2012.02.002.Macpherson A.J., Geuking M. B., McCoy K. D. Homeland security: IgA immunity at the frontiers of the body. Trends Immunol. 2012 Apr;33(4):160-7. doi: 10.1016/j.it.2012.02.002.Chopyk D.M., Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology. 2020 Sep;159(3):849-863. doi: 10.1053/j.gastro.2020.04.077.Chopyk D.M., Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology. 2020 Sep;159(3):849-863. doi: 10.1053/j.gastro.2020.04.077.Bennett K.M., Walker S. L., Lo D. D. Epithelial microvilli establish an electrostatic barrier to microbial adhesion. Infect Immun. 2014 Jul;82(7):2860-71. doi: 10.1128/IAI.01681-14.Bennett K.M., Walker S. L., Lo D. D. Epithelial microvilli establish an electrostatic barrier to microbial adhesion. Infect Immun. 2014 Jul;82(7):2860-71. doi: 10.1128/IAI.01681-14.Van Itallie C. M., Anderson J. M. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. 2014 Dec;36:157-65. doi: 10.1016/j.semcdb.2014.08.011.Van Itallie C. M., Anderson J. M. Architecture of tight junctions and principles of molecular composition. Semin Cell Dev Biol. 2014 Dec;36:157-65. doi: 10.1016/j.semcdb.2014.08.011.Luissint A.C., Parkos C. A., Nusrat A. Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair. Gastroenterology. 2016 Oct;151(4):616-32. doi: 10.1053/j.gastro.2016.07.008.Luissint A.C., Parkos C. A., Nusrat A. Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair. Gastroenterology. 2016 Oct;151(4):616-32. doi: 10.1053/j.gastro.2016.07.008.Dommett R., Zilbauer M., George J. T., Bajaj-Elliott M. Innate immune defence in the human gastrointestinal tract. Mol. Immunol. 2005;42:903-912. doi: 10.1016/j.molimm.2004.12.004.Dommett R., Zilbauer M., George J. T., Bajaj-Elliott M. Innate immune defence in the human gastrointestinal tract. Mol. Immunol. 2005;42:903-912. doi: 10.1016/j.molimm.2004.12.004.Meyer-Hoffert U., Hornef M. W., Henriques-Normark B., Axelsson L. G., Midtvedt T., Putsep K., Andersson M. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut. 2008;57:764-771. doi: 10.1136/gut.2007.141481.Meyer-Hoffert U., Hornef M. W., Henriques-Normark B., Axelsson L. G., Midtvedt T., Putsep K., Andersson M. Secreted enteric antimicrobial activity localises to the mucus surface layer. Gut. 2008;57:764-771. doi: 10.1136/gut.2007.141481.Wiest R., Lawson M., Geuking M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 2014;60:197-209. doi: 10.1016/j.jhep.2013.07.044.Wiest R., Lawson M., Geuking M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 2014;60:197-209. doi: 10.1016/j.jhep.2013.07.044.Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A., Caprioli F., Bottiglieri L., Oldani A., Viale G., et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830-834. doi: 10.1126/science.aad0135.Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A., Caprioli F., Bottiglieri L., Oldani A., Viale G., et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015;350:830-834. doi: 10.1126/science.aad0135.Balmer M.L., Slack E., de Gottardi A., Lawson M. A., Hapfelmeier S., Miele L., Grieco A., Van Vlierberghe H., Fahrner R., Patuto N., et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci. Transl. Med. 2014;6:237ra266. doi: 10.1126/scitranslmed.3008618.Balmer M.L., Slack E., de Gottardi A., Lawson M. A., Hapfelmeier S., Miele L., Grieco A., Van Vlierberghe H., Fahrner R., Patuto N., et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci. Transl. Med. 2014;6:237ra266. doi: 10.1126/scitranslmed.3008618.Wood N. J. Liver: The liver as a firewall - clearance of commensal bacteria that have escaped from the gut. Nat. Rev. Gastroenterol. Hepatol. 2014;11:391. doi: 10.1038/nrgastro.2014.90.Wood N. J. Liver: The liver as a firewall - clearance of commensal bacteria that have escaped from the gut. Nat. Rev. Gastroenterol. Hepatol. 2014;11:391. doi: 10.1038/nrgastro.2014.90.Maynard C.L., Elson C. O., Hatton R. D., Weaver C. T. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489:231-241. doi: 10.1038/nature11551.Maynard C.L., Elson C. O., Hatton R. D., Weaver C. T. Reciprocal interactions of the intestinal microbiota and immune system. Nature. 2012;489:231-241. doi: 10.1038/nature11551.Macpherson A.J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303:1662-1665. doi: 10.1126/science.1091334.Macpherson A.J., Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science. 2004;303:1662-1665. doi: 10.1126/science.1091334.Etienne-Mesmin L., Vijay-Kumar M., Gewirtz A. T., Chassaing B. Hepatocyte Toll-Like Receptor 5 Promotes Bacterial Clearance and Protects Mice Against High-Fat Diet-Induced Liver Disease. Cell Mol. Gastroenterol. Hepatol. 2016;2:584-604. doi: 10.1016/j.jcmgh.2016.04.007.Etienne-Mesmin L., Vijay-Kumar M., Gewirtz A. T., Chassaing B. Hepatocyte Toll-Like Receptor 5 Promotes Bacterial Clearance and Protects Mice Against High-Fat Diet-Induced Liver Disease. Cell Mol. Gastroenterol. Hepatol. 2016;2:584-604. doi: 10.1016/j.jcmgh.2016.04.007.Lee W.Y., Moriarty T. J., Wong C. H., Zhou H., Strieter R. M., van Rooijen N., Chaconas G., Kubes P. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat. Immunol. 2010;11:295-302. doi: 10.1038/ni.1855.Lee W.Y., Moriarty T. J., Wong C. H., Zhou H., Strieter R. M., van Rooijen N., Chaconas G., Kubes P. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat. Immunol. 2010;11:295-302. doi: 10.1038/ni.1855.Schwabe R.F., Seki E., Brenner D. A. Toll-like receptor signaling in the liver. Gastroenterology. 2006;130:1886-1900. doi: 10.1053/j.gastro.2006.01.038.Schwabe R.F., Seki E., Brenner D. A. Toll-like receptor signaling in the liver. Gastroenterology. 2006;130:1886-1900. doi: 10.1053/j.gastro.2006.01.038.Simanenkov V.I., Maev I. V., Tkacheva O. N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi:10.15829/1728-8800-2021-2758.@@ Симаненков В. И., Маев И. В., Ткачева О.Н, и соавт. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi:10.15829/1728-8800-2021-2758.Simanenkov V.I., Maev I. V., Tkacheva O. N. et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi:10.15829/1728-8800-2021-2758.@@ Симаненков В. И., Маев И. В., Ткачева О.Н, и соавт. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. doi:10.15829/1728-8800-2021-2758.Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020 Jan 31;9: F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1.Fasano A. All disease begins in the (leaky) gut: role of zonulin-mediated gut permeability in the pathogenesis of some chronic inflammatory diseases. F1000Res. 2020 Jan 31;9: F1000 Faculty Rev-69. doi: 10.12688/f1000research.20510.1.Kinashi Y., Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol. 2021 Apr 22;12:673708. doi: 10.3389/fimmu.2021.673708.Kinashi Y., Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunol. 2021 Apr 22;12:673708. doi: 10.3389/fimmu.2021.673708.Christovich A., Luo X. M. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. Front Immunol. 2022 Jun 27;13:946248. doi: 10.3389/fimmu.2022.946248.Christovich A., Luo X. M. Gut Microbiota, Leaky Gut, and Autoimmune Diseases. Front Immunol. 2022 Jun 27;13:946248. doi: 10.3389/fimmu.2022.946248.Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019 Aug;68(8):1516-1526. doi: 10.1136/gutjnl-2019-318427.Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019 Aug;68(8):1516-1526. doi: 10.1136/gutjnl-2019-318427.Odenwald M.A., Turner J. R.Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013 Sep;11(9):1075-83. doi: 10.1016/j.cgh.2013.07.001.Odenwald M.A., Turner J. R.Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013 Sep;11(9):1075-83. doi: 10.1016/j.cgh.2013.07.001.Fritscher-Ravens A., Schuppan D., Ellrichmann M. et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1012-20.e4. doi: 10.1053/j.gastro.2014.07.046.Fritscher-Ravens A., Schuppan D., Ellrichmann M. et al. Confocal endomicroscopy shows food-associated changes in the intestinal mucosa of patients with irritable bowel syndrome. Gastroenterology. 2014 Nov;147(5):1012-20.e4. doi: 10.1053/j.gastro.2014.07.046.Peters S.A., Edogawa S., Sundt W. J. et al. Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. Am J Gastroenterol. 2017 Jun;112(6):913-923. doi: 10.1038/ajg.2017.48.Peters S.A., Edogawa S., Sundt W. J. et al. Constipation-Predominant Irritable Bowel Syndrome Females Have Normal Colonic Barrier and Secretory Function. Am J Gastroenterol. 2017 Jun;112(6):913-923. doi: 10.1038/ajg.2017.48.Kessoku T., Kobayashi T., Tanaka K. et al. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.Int J Mol Sci. 2021 Jul 29;22(15):8161. doi: 10.3390/ijms22158161.Kessoku T., Kobayashi T., Tanaka K. et al. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.Int J Mol Sci. 2021 Jul 29;22(15):8161. doi: 10.3390/ijms22158161.Miele L., Valenza V., La Torre G. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887. doi: 10.1002/hep.22848.Miele L., Valenza V., La Torre G. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49:1877-1887. doi: 10.1002/hep.22848.Cani P.D., Amar J., Iglesias M. A. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772. doi: 10.2337/db06-1491.Cani P.D., Amar J., Iglesias M. A. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761-1772. doi: 10.2337/db06-1491.Grover M., Kanazawa M., Palsson O. S., Chitkara D. K., Gangarosa L. M., Drossman D. A., Whitehead W. E. Small intestinal bacterial overgrowth in irritable bowel syndrome: Association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol. Motil. 2008;20:998-1008. doi: 10.1111/j.1365-2982.2008.01142.x.Grover M., Kanazawa M., Palsson O. S., Chitkara D. K., Gangarosa L. M., Drossman D. A., Whitehead W. E. Small intestinal bacterial overgrowth in irritable bowel syndrome: Association with colon motility, bowel symptoms, and psychological distress. Neurogastroenterol. Motil. 2008;20:998-1008. doi: 10.1111/j.1365-2982.2008.01142.x.Lichtman S.N., Keku J., Schwab J. H., Sartor R. B. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology. 1991;100:513-519. doi: 10.1016/0016-5085(91)90224-9.Lichtman S.N., Keku J., Schwab J. H., Sartor R. B. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology. 1991;100:513-519. doi: 10.1016/0016-5085(91)90224-9.Bergheim I., Weber S., Vos M., Krämer S., Volynets V., Kaserouni S., McClain C.J., Bischoff S. C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J. Hepatol. 2008;48:983-992. doi: 10.1016/j.jhep.2008.01.035.Bergheim I., Weber S., Vos M., Krämer S., Volynets V., Kaserouni S., McClain C.J., Bischoff S. C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J. Hepatol. 2008;48:983-992. doi: 10.1016/j.jhep.2008.01.035.Kobayashi T., Iwaki M., Nakajima A., Nogami A., Yoneda M. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.Int J Mol Sci. 2022 Oct 2;23(19):11689. doi: 10.3390/ijms231911689.Kobayashi T., Iwaki M., Nakajima A., Nogami A., Yoneda M. Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome.Int J Mol Sci. 2022 Oct 2;23(19):11689. doi: 10.3390/ijms231911689.Harte A.L., da Silva N. F., Creely S. J. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. 2010;7:15. doi: 10.1186/1476-9255-7-15.Harte A.L., da Silva N. F., Creely S. J. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. 2010;7:15. doi: 10.1186/1476-9255-7-15.Pendyala S., Walker J. M., Holt P. R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142:1100-1101.e2. doi: 10.1053/j.gastro.2012.01.034.Pendyala S., Walker J. M., Holt P. R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology. 2012;142:1100-1101.e2. doi: 10.1053/j.gastro.2012.01.034.Boursier J., Mueller O., Barret M. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-775. doi: 10.1002/hep.28356.Boursier J., Mueller O., Barret M. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764-775. doi: 10.1002/hep.28356.Leung C., Rivera L., Furness J. B., Angus P. W. The role of the gut microbiota in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2016;13:412-425. doi: 10.1038/nrgastro.2016.85.Leung C., Rivera L., Furness J. B., Angus P. W. The role of the gut microbiota in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2016;13:412-425. doi: 10.1038/nrgastro.2016.85.Zhu L., Baker S. S., Gill C., Liu W., Alkhouri R., Baker R. D., Gill S. R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609. doi: 10.1002/hep.26093.Zhu L., Baker S. S., Gill C., Liu W., Alkhouri R., Baker R. D., Gill S. R. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2013;57:601-609. doi: 10.1002/hep.26093.Dawes E.A., Foster S. M. The formation of ethanol in Escherichia coli. Biochim. Biophys. Acta. 1956;22:253-265. doi: 10.1016/0006-3002(56)90148-2.Dawes E.A., Foster S. M. The formation of ethanol in Escherichia coli. Biochim. Biophys. Acta. 1956;22:253-265. doi: 10.1016/0006-3002(56)90148-2.Baker S.S., Baker R. D., Liu W., Nowak N. J., Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE. 2010;5: e9570. doi: 10.1371/journal.pone.0009570.Baker S.S., Baker R. D., Liu W., Nowak N. J., Zhu L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS ONE. 2010;5: e9570. doi: 10.1371/journal.pone.0009570.Zhu L., Baker R. D., Zhu R., Baker S. S. Gut microbiota produce alcohol and contribute to NAFLD. Gut. 2016;65:1232. doi: 10.1136/gutjnl-2016-311571.Zhu L., Baker R. D., Zhu R., Baker S. S. Gut microbiota produce alcohol and contribute to NAFLD. Gut. 2016;65:1232. doi: 10.1136/gutjnl-2016-311571.Guercio Nuzio S., Di Stasi M., Pierri L., Troisi J. et al. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr. Obes. 2017;12:446-452. doi: 10.1111/ijpo.12164.Guercio Nuzio S., Di Stasi M., Pierri L., Troisi J. et al. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr. Obes. 2017;12:446-452. doi: 10.1111/ijpo.12164.Lim J.S., Mietus-Snyder M., Valente A., Schwarz J. M., Lustig R. H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010 May;7(5):251-64. doi: 10.1038/nrgastro.2010.41.Lim J.S., Mietus-Snyder M., Valente A., Schwarz J. M., Lustig R. H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010 May;7(5):251-64. doi: 10.1038/nrgastro.2010.41.Softic S., Gupta M. K., Wang G. X. et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest. 2017 Nov 1;127(11):4059-4074. doi: 10.1172/JCI94585.Softic S., Gupta M. K., Wang G. X. et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest. 2017 Nov 1;127(11):4059-4074. doi: 10.1172/JCI94585.Cho Y.E., Kim D. K., Seo W., Gao B., Yoo S. H., Song B. J. Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. Hepatology. 2021 Jun;73(6):2180-2195. doi: 10.1002/hep.30652.Cho Y.E., Kim D. K., Seo W., Gao B., Yoo S. H., Song B. J. Fructose Promotes Leaky Gut, Endotoxemia, and Liver Fibrosis Through Ethanol-Inducible Cytochrome P450-2E1-Mediated Oxidative and Nitrative Stress. Hepatology. 2021 Jun;73(6):2180-2195. doi: 10.1002/hep.30652.Nicoletti A., Ponziani F. R., Biolato M., Valenza V., Marrone G., Sganga G., Gasbarrini A., Miele L., Grieco A.Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J. Gastroenterol. 2019;25:4814-4834. doi: 10.3748/wjg.v25.i33.4814.Nicoletti A., Ponziani F. R., Biolato M., Valenza V., Marrone G., Sganga G., Gasbarrini A., Miele L., Grieco A.Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World J. Gastroenterol. 2019;25:4814-4834. doi: 10.3748/wjg.v25.i33.4814.Paradis T., Bègue H., Basmaciyan L., Dalle F., Bon F. Tight Junctions as a Key for Pathogens Invasion in Intestinal Epithelial Cells.Int. J. Mol. Sci. 2021;22:2506. doi: 10.3390/ijms22052506.Paradis T., Bègue H., Basmaciyan L., Dalle F., Bon F. Tight Junctions as a Key for Pathogens Invasion in Intestinal Epithelial Cells.Int. J. Mol. Sci. 2021;22:2506. doi: 10.3390/ijms22052506.Fukui H. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut Liver. 2021 Sep 15;15(5):666-676. doi: 10.5009/gnl20032.Fukui H. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update. Gut Liver. 2021 Sep 15;15(5):666-676. doi: 10.5009/gnl20032.Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015 Mar 27;7(3):425-42. doi: 10.4254/wjh.v7.i3.425.Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015 Mar 27;7(3):425-42. doi: 10.4254/wjh.v7.i3.425.Yu L.X., Schwabe R. F. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):527-539. doi: 10.1038/nrgastro.2017.72.Yu L.X., Schwabe R. F. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):527-539. doi: 10.1038/nrgastro.2017.72.Kawaguchi T., Torimura T. Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol. 2022 Apr;28(2):177-180. doi: 10.3350/cmh.2021.0246.Kawaguchi T., Torimura T. Leaky gut-derived tumor necrosis factor-α causes sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol. 2022 Apr;28(2):177-180. doi: 10.3350/cmh.2021.0246.Carpi R.Z., Barbalho S. M., Sloan K. P. et al. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.Int J Mol Sci. 2022 Aug 8;23(15):8805. doi: 10.3390/ijms23158805.Carpi R.Z., Barbalho S. M., Sloan K. P. et al. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.Int J Mol Sci. 2022 Aug 8;23(15):8805. doi: 10.3390/ijms23158805.Darmov I.V., Chicherin I. Yu. Pogorelsky I. P., Lundovskikh I. A., Durnev E. A. Survival of probiotic microorganisms in the gastrointestinal tract of experimental animals. Journal infectology. 2012;1(4):68-74. (in Russ.)@@ Дармов И. В., Чичерин И. Ю. Погорельский И. П., Лундовских И. А., Дурнев Е. А. Выживаемость микроорганизмов пробиотиков в желудочно-кишечном тракте экспериментальных животных. Журн. инфектологии. 2012;1(4):68-74.Darmov I.V., Chicherin I. Yu. Pogorelsky I. P., Lundovskikh I. A., Durnev E. A. Survival of probiotic microorganisms in the gastrointestinal tract of experimental animals. Journal infectology. 2012;1(4):68-74. (in Russ.)@@ Дармов И. В., Чичерин И. Ю. Погорельский И. П., Лундовских И. А., Дурнев Е. А. Выживаемость микроорганизмов пробиотиков в желудочно-кишечном тракте экспериментальных животных. Журн. инфектологии. 2012;1(4):68-74.Darmov IV, Chicherin IIu, Pogorel’skiĭ IP, Lundovskikh IA. [Survival of probiotic microorganisms in the conditions in vitro imitating the process of human digestion]. Eksp Klin Gastroenterol. 2011;(3):6-11.Russian. PMID: 21695946.@@ Дармов И. В., Чичерин И. Ю., Погорельский И. П., Лундовских И. А. Выживаемость микроорганизмов пробиотиков в условиях in vitro, имитирующих процесс пищеварения у человека. Экспериментальная и клиническая гастроэнтерология. 2011;3: 6-11.Darmov IV, Chicherin IIu, Pogorel’skiĭ IP, Lundovskikh IA. [Survival of probiotic microorganisms in the conditions in vitro imitating the process of human digestion]. Eksp Klin Gastroenterol. 2011;(3):6-11.Russian. PMID: 21695946.@@ Дармов И. В., Чичерин И. Ю., Погорельский И. П., Лундовских И. А. Выживаемость микроорганизмов пробиотиков в условиях in vitro, имитирующих процесс пищеварения у человека. Экспериментальная и клиническая гастроэнтерология. 2011;3: 6-11.Chicherin I. Yu., Darmov I. V., Pogorelsky I. P., Lundovskikh I. A., Gavrilov K. E. Survival of bifidobacteria and lactobacilli in vitro in gastric juice and duodenal contents of people. Medical almanac. 2012;1: 57-59. (in Russ.)@@ Чичерин И. Ю., Дармов И. В., Погорельский И. П., Лундовских И. А., Гаврилов К. Е. Выживаемость бифидо-бактерий и лактобактерий в условиях in vitro в желудочном соке и дуоденальном содержимом людей. Медицинский альманах. 2012;1: 57-59.Chicherin I. Yu., Darmov I. V., Pogorelsky I. P., Lundovskikh I. A., Gavrilov K. E. Survival of bifidobacteria and lactobacilli in vitro in gastric juice and duodenal contents of people. Medical almanac. 2012;1: 57-59. (in Russ.)@@ Чичерин И. Ю., Дармов И. В., Погорельский И. П., Лундовских И. А., Гаврилов К. Е. Выживаемость бифидо-бактерий и лактобактерий в условиях in vitro в желудочном соке и дуоденальном содержимом людей. Медицинский альманах. 2012;1: 57-59.Chicherin I. Yu., Pogorelsky I. P., Lundovskikh I. A., Darmov I. V., Shabalina M. R., Podvolotsky A. N.Comparative experimental evaluation of the effectiveness of modern probiotics, prebiotics, synbiotics and metabiotics for correction of intestinal microbiocenosis in animals with antibiotic-associated dysbiosis. Experimental and Clinical Gastroenterology. 2016;(7):106-120. (In Russ.)@@ Чичерин И. Ю., Погорельский И. П., Лундовских И. Г., Дармов И. В., Шабалина М. Р., Подволоцкий А. С. Сравнительная экспериментальная оценка эффективности современных пробиотиков, пребиотиков, синбиотиков и метабиотиков при коррекции нарушений микробиоценоза кишечника у животных с антибиотико-ассоциированным дисбиозом. Экспериментальная и клиническая гастроэнтерология. 2016;7(131):106-120.Chicherin I. Yu., Pogorelsky I. P., Lundovskikh I. A., Darmov I. V., Shabalina M. R., Podvolotsky A. N.Comparative experimental evaluation of the effectiveness of modern probiotics, prebiotics, synbiotics and metabiotics for correction of intestinal microbiocenosis in animals with antibiotic-associated dysbiosis. Experimental and Clinical Gastroenterology. 2016;(7):106-120. (In Russ.)@@ Чичерин И. Ю., Погорельский И. П., Лундовских И. Г., Дармов И. В., Шабалина М. Р., Подволоцкий А. С. Сравнительная экспериментальная оценка эффективности современных пробиотиков, пребиотиков, синбиотиков и метабиотиков при коррекции нарушений микробиоценоза кишечника у животных с антибиотико-ассоциированным дисбиозом. Экспериментальная и клиническая гастроэнтерология. 2016;7(131):106-120.Minushkin O.N., Maslovsky L. V., Ardatskaya M. D., Bulanova M. I., Beilina N. I., Kolodkin A. M., Zverkov I. V., Gordienko E. S. Clinical and metabolic effects of metaprebiotic therapy for some functional bowel diseases. Experimental and Clinical Gastroenterology. 2021;(10):100-108. (In Russ.) doi: 10.31146/1682-8658-ecg-194-10-100-108.@@ Минушкин О. Н., Масловский Л. В., Ардатская М. Д., Буланова М. И., Бейлина Н. И., Колодкин А. М., Зверков И. В., Гордиенко Е. С. Клинико- метаболические эффекты терапии метапребиотиками некоторых функциональных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;194(10): 100-108. doi: 10.31146/1682-8658-ecg-194-10-100-108.Minushkin O.N., Maslovsky L. V., Ardatskaya M. D., Bulanova M. I., Beilina N. I., Kolodkin A. M., Zverkov I. V., Gordienko E. S. Clinical and metabolic effects of metaprebiotic therapy for some functional bowel diseases. Experimental and Clinical Gastroenterology. 2021;(10):100-108. (In Russ.) doi: 10.31146/1682-8658-ecg-194-10-100-108.@@ Минушкин О. Н., Масловский Л. В., Ардатская М. Д., Буланова М. И., Бейлина Н. И., Колодкин А. М., Зверков И. В., Гордиенко Е. С. Клинико- метаболические эффекты терапии метапребиотиками некоторых функциональных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2021;194(10): 100-108. doi: 10.31146/1682-8658-ecg-194-10-100-108.Safronova A.I., Pyrieva E. A., Timoshina M. I., Toboleva M. A., Kolodkin A. M. Experience of using metaprebiotic products in the nutrition of children with constipation. Vopr. det. dietol. (Pediatric Nutrition). 2023; 21(4): 33-40. (In Russ.) doi: 10.20953/1727-5784-2023-4-33-40.@@ Сафронова А. И., Пырьева Е. А., Тимошина М. И., Тоболева М. А., Колодкин А. М. Опыт использования метапребиотических продуктов в питании детей с запорами. Вопросы детской диетологии. 2023; 21(4): 33-40. doi: 10.20953/1727-5784-2023-4-33-40.Safronova A.I., Pyrieva E. A., Timoshina M. I., Toboleva M. A., Kolodkin A. M. Experience of using metaprebiotic products in the nutrition of children with constipation. Vopr. det. dietol. (Pediatric Nutrition). 2023; 21(4): 33-40. (In Russ.) doi: 10.20953/1727-5784-2023-4-33-40.@@ Сафронова А. И., Пырьева Е. А., Тимошина М. И., Тоболева М. А., Колодкин А. М. Опыт использования метапребиотических продуктов в питании детей с запорами. Вопросы детской диетологии. 2023; 21(4): 33-40. doi: 10.20953/1727-5784-2023-4-33-40.

The authors declare that there are no conflicts of interest present.